within Pharmacolibrary.Drugs.ATC.L;

model L04AC13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.54,
    Cl             = 0.0002683333333333333,
    adminDuration  = 600,
    adminMass      = 0.16,
    adminCount     = 1,
    Vd             = 0.00711,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a pro-inflammatory cytokine. It is used for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Ixekizumab is approved by regulatory agencies, including the FDA and EMA, for these indications.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with moderate-to-severe plaque psoriasis. Parameters were evaluated following subcutaneous administration in both males and females, aged 18 to 75 years.</p><h4>References</h4><ol><li><p>Callis Duffin, K, et al., &amp; Jackson, K (2017). Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). <i>Journal of the European Academy of Dermatology and Venereology : JEADV</i> 31(1) 107–113. DOI:<a href=&quot;https://doi.org/10.1111/jdv.13768&quot;>10.1111/jdv.13768</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27500949/&quot;>https://pubmed.ncbi.nlm.nih.gov/27500949</a></p></li><li><p>Zheng, M, et al., &amp; Zheng, J (2023). Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study. <i>Advances in therapy</i> 40(9) 3804–3816. DOI:<a href=&quot;https://doi.org/10.1007/s12325-023-02575-1&quot;>10.1007/s12325-023-02575-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37356077/&quot;>https://pubmed.ncbi.nlm.nih.gov/37356077</a></p></li><li><p>Hanley, TL, &amp; Yiu, ZZ (2017). Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. <i>Therapeutics and clinical risk management</i> 13 315–323. DOI:<a href=&quot;https://doi.org/10.2147/TCRM.S111107&quot;>10.2147/TCRM.S111107</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28352182/&quot;>https://pubmed.ncbi.nlm.nih.gov/28352182</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC13;
